forbidden word: fetal tissue research
National Institute of Health Grants Policy Statement
REVISED MARCH 2026. This document supersedes the April 2024 version of the NIHGPS.
4.1.15 Human Fetal Tissue Research
Human fetal tissue is defined as tissue or cells obtained from a dead human embryo or fetus after a spontaneous or induced abortion or stillbirth. This definition does not include established human fetal cell lines.
Sections 498A and 498B of the PHS Act (42 U.S.C. 289g-1 and 289g-2) set forth specific requirements and prohibitions on research involving human fetal tissue. Research involving human fetal tissue is also subject to the HHS Regulations for the Protection of Human Subjects. 45 C.F.R. 46.204 and 46.206 may be specifically relevant.
The scientific and ethical challenges associated with research utilizing human fetal tissue make it imperative that researchers and their organizations be fully aware of and in compliance with the Federal requirements. When an application involving human fetal tissue research is submitted to NIH, the AOR’s signature certifies that researchers using these tissues are in compliance with the PHS Act. The statute specifically prohibits any person from knowingly acquiring, receiving, or transferring any human fetal tissue for valuable consideration. The term “valuable consideration” is a concept similar to profit and does not include reasonable payment for costs associated with the collection, processing, preservation, storage, quality control, or transportation of these tissues. Violation of this statute carries criminal penalties that apply to both those that supply and those that acquire human fetal tissue.
Current federal laws and regulations require informed consent for research involving the transplantation of human fetal tissue and for research with human fetal material associated with information that can identify a living individual. Most states require informed consent for the use of fetal tissue in research. Accordingly, NIH expects informed consent to have been obtained from the donor for any NIH-funded research using human fetal tissue.
When obtaining primary human fetal tissue for research purposes, NIH expects recipients to maintain appropriate documentation.
4.1.15.1 Research on Transplantation of Human Fetal Tissue
Sections 498A and 498B contain additional requirements for research on the transplantation of human fetal tissue for therapeutic purposes conducted or supported by NIH. Research involving the transplantation of human fetal tissue must be conducted in accordance with applicable Federal, State and local laws as well as the following NIH guidance.
Under section 498A, the official who signs the application is certifying that the research on transplantation of human fetal tissue will adhere to the following provisions:
- The woman who donates the fetal tissue must sign a statement declaring that the donation is being made:
- for therapeutic transplantation research,
- without any restriction regarding the identity of individuals who may receive the transplantation, and
- without the donor knowing the identity of the recipient.
- The attending physician must sign a statement that they have:
- obtained the tissue in accordance with the donor’s signed statement and
- fully disclosed to the donor their intent, if any, to use the tissue in research and any known medical risks to the donor or risks to her privacy associated with the donation that are in addition to risks associated with the woman’s medical care.
- In the case of tissue obtained pursuant to an induced abortion, the physician’s statement also must state that they:
- obtained the woman’s consent for the abortion before requesting or obtaining consent for the tissue to be used;
- did not alter the timing, method, or procedures used to terminate the pregnancy solely for the purpose of obtaining the tissue for research; and
- performed the abortion in accordance with applicable State and local laws.
- The PD/PI must sign a statement certifying that they are aware that the tissue is human fetal tissue obtained in a spontaneous or induced abortion, or pursuant to a stillbirth and that the tissue was donated for research purposes. The PD/PI also must certify that this information has been shared with others who have responsibilities regarding the research and, before eliciting informed consent from the transplantation recipient, will obtain written acknowledgment that the patient is aware of the aforementioned information.
- The PD/PI must certify in writing that they have had no part in any decisions as to the timing, method, or procedures used to terminate the pregnancy.
In submitting an application to NIH, the AOR that signs the application is certifying that, if research on the transplantation of human fetal tissue is conducted under the grant-supported project, the organization will make available for audit by the HHS Secretary or designee, the physician statements, the PD/PI’s statements, and informed consents required by subsections 498A(b)(2) and (c) of the PHS Act or will ensure HHS access to those records, if maintained by an entity other than the recipient. This requirement is in addition to the requirements concerning human subjects in research.
In addition, FDA has jurisdiction over fetal cells and tissues intended for use in humans and requests that investigators contact them to determine whether any planned or ongoing clinical research would require submission of an IND application. Additional information and FDA contact information is available on FDA’s Safety & Availability (Biologics) webpage.
4.1.15.2 Non-Transplantation Research on Human Fetal Tissue from Elective Abortions
For the purposes of this section, HFT from elective abortions is defined as research involving the study, analysis, or use of primary HFT, cells, and derivatives, and human fetal primary cell cultures obtained from elective abortions and includes the following:
• human fetal primary or secondary cell cultures, whether derived by the investigator or obtained from a vendor.
• animal models incorporating HFT from elective abortions, including obtaining such models from a vendor.
• derivative products from elective abortion tissues or cells such as protein or nucleic acid extracts.
• any human extra-embryonic cells and tissue, such as umbilical cord tissue, cord blood, placenta, amniotic fluid, and chorionic villi, if obtained from the process of elective abortion.
• The definition of research involving HFT from elective abortions does not include the following:
-
-
human fetal primary or secondary cell cultures, if cells were not derived from an elective abortion
-
already-established (as of June 5, 2019) human fetal cell lines (e.g., induced pluripotent stem cell lines from human fetal tissue, immortalized cell lines, differentiated cell lines).
-
derivative products from human fetal tissue or cells (e.g., DNA, RNA, protein) if not derived from elective abortion.
-
human extra-embryonic cells and tissue, including, but not limited to, umbilical cord tissue, cord blood, placenta, amniotic fluid, and chorionic villi if not derived from elective abortion.
-
human fetal cells present in maternal blood or other maternal sources
-
human embryonic stem cells or human embryonic cell lines.
-
research on transplantation of HFT for therapeutic purposes (because of the statutory provision(s) addressing such research).”
-
Effective January 22, 2026, NIH funds are not permitted for research using HFT from elective abortions.
from — NIH. (n.d.). 4.1.14 Human fetal tissue research.
University of Pittsburgh: Human Cell and Tissue Research
Facts About Fetal Tissue Research
FACT: America’s top biomedical research institutions utilize fetal tissue for certain types of research. In 2020, the top-10 NIH-funded institutions—the University of Pittsburgh included—received NIH grants for projects that utilize fetal tissue research.
FACT: Research utilizing fetal tissue research plays a vital role in making new discoveries and developing products for protecting and promoting human health. In fact, no FDA-approved medication or treatment available today has been approved for use without first originating from discoveries made utilizing human cells or tissue.
FACT: Most people have already benefited from research utilizing fetal cell and tissue —they just might not know it. Scientists have used fetal cell lines to develop and test lifesaving vaccines, including those that protect against COVID-19, polio, chickenpox, shingles, measles, rubella, rabies and hepatitis A. They have used fetal tissues and fetal cell lines to better understand how to support a healthy pregnancy and healthy babies, and to develop a number of medications—now available—for treating cancer, diabetes, heart disease, rheumatoid arthritis, cystic fibrosis, hemophilia and more.
FACT: Research involving fetal tissue is tightly regulated. Researchers must follow strict regulatory requirements at both the state and federal level. In fact, Pennsylvania’s General Assembly has already enacted some of the nation’s strictest state-level limitations on fetal tissue research.
FACT: Fetal cell and tissue research isn’t new. Human cell lines, derived from fetal tissues, have been immortalized such that they reproduce indefinitely and can be used again and again in research. In fact, scientists still use the WI-38 and MRC-5 immortalized fetal cell lines, derived from fetal tissues obtained in Sweden in 1962 and the United Kingdom in 1966. These cell lines contributed to the development of vaccines for polio, rubella and other diseases that have saved millions of lives.
FACT: At present, for certain types of experiments studying mechanisms that are unique to human diseases, there is no substitute for human fetal tissue cells. These cells grow readily and adapt to laboratory environments, allowing researchers to study basic human biology and normal human development in a way that cannot be replicated with adult tissue.
FACT: There are no monetary gains—only scientific gains—tied to collecting fetal cells and tissue for research. The NIH and Pennsylvania law expressly forbid entities from profiting off the collection, cataloging, storage and transfer of fetal tissue donations.
FACT: Voluntary donation and informed consent is required by law for fetal tissue to be collected for and provided to researchers. As with all human tissue research, responsible adults must consent to donate—whether the tissue originates from themselves, their children or an unborn fetus.
FACT: The voluntary donation of fetal tissue is completely independent of research utilizing previously collected fetal tissue. Research teams have no role in obtaining consent to donate tissue.
FACT: Stopping fetal tissue research would be detrimental to:
Patients: Babies, kids and adults would be deprived of forthcoming treatments and discoveries, many of which will be lifesaving. We will be unable to find new treatments for nearly 6000 human diseases for which there are no treatments available today.
Pennsylvania: Pennsylvania’s premiere biomedical research institutions would see their capacity to innovate shrink, as researchers and research funding left for institutions in other states.
America: The nation’s workforce would fall behind the rest of the world in developing cutting edge medical treatments and advancements. We will no longer be the first in the world to gain access to new therapies that would have otherwise been developed here in the United States.
Trump imposes new NIH funding ban on human fetal tissue research
Agency may also be moving toward restricting use of embryonic stem cells
The National Institutes of Health (NIH) announced Thursday it will no longer fund research involving human fetal tissue from elective abortions. The widely anticipated decision, which could halt dozens of extramural projects, goes further than restrictions President Donald Trump imposed to satisfy abortion opponents during his first term.
“NIH is pushing American biomedical science into the 21st century,” agency Director Jayanta “Jay” Bhattacharya said in a statement announcing the change. “This decision is about advancing science by investing in breakthrough technologies more capable of modeling human health and disease.”
The new ban is “clearly a political decision” rather than a scientific one, says Lawrence Goldstein, a neuroscientist at the University of California (UC) San Diego and outspoken advocate of the research. The International Society for Stem Cell Research also objected to the new policy, which it calls “highly disruptive,” writing in a statement that human fetal tissue “remains a necessary tool for addressing certain research questions that cannot yet be adequately answered by organoids, tissue chips, and other emerging technologies.”
The policy takes effect immediately and applies to both intramural, or in-house projects, and extramural grants, NIH said. Although “NIH funds will not be permitted for research using” human fetal tissue, projects already in progress can continue if those funds are “rebudgeted” for other research, according to a notice outlining the policy. “NIH will work with the institutions to take appropriate steps to ensure compliance,” the agency press team wrote in an email to Science.
UC Los Angeles HIV researcher Jerome Zack, who has an affected project, said the “instantaneous nature” of the policy was a surprise and he expects to be told that ongoing experiments must stop. That “could be quite wasteful” for some lab work, such as animal studies, he says.
During Trump’s first term in office, the Department of Health and Human Services (HHS) banned NIH’s intramural scientists from conducting research using human fetal tissue, disrupting studies on HIV, cancer, and coronaviruses. The agency allowed university researchers with ongoing grants to continue, but those applying for new grants had to undergo a lengthy review by an ethics advisory board. That board, dominated by ethicists and scientists who opposed abortion, ultimately rejected the vast majority of proposals it reviewed. Former President Joe Biden’s administration later scrapped these restrictions.
In its announcement, NIH noted its funding of research using human fetal tissue has declined since 2018, with only 77 grants totaling $53 million—a small fraction of the agency’s $48 billion budget—supported in fiscal year 2024, a trend that likely reflects restrictions imposed during the first Trump administration. Nine of those projects are intramural and, according to multiple NIH sources, some do not currently use fetal tissue.
Of the roughly 60 extramural grants on the list that aren’t duplicates, work ranges from studies of HIV treatments that use mice with “humanized” immune systems to research on diabetes, cancer, and brain development. However, some of the studies have likely ended, and others may not have actually used the controversial material, according to reporting by Science in September 2025, when NIH said it would not renew funding for 17 active projects.
NIH described organoids, tissue chips, and other platforms as “robust alternatives” to human fetal tissue. But Zack says although “there are workarounds” for his research using humanized mice, “it is very difficult to answer some questions without using fetal tissue.” The new policy “will not shut us down, but it will set us back.” Another HIV researcher with grants on the list said if “proven alternatives” existed, he “would gladly use them.” The researcher, who asked not to be named because his institution had not cleared him to comment, adds: “In the end, we are sacrificing the best science in the name of politics.”
Goldstein says fetal tissue also provides unique insights into human development that cannot be replicated using other methods. “If you want to deduce the actual molecular features of human organ development during fetal stages and if you want to be sure you’re making the right kinds of cells from stem cells,” he says, “you need actual fetal tissue.” Although NIH funds are still permitted for research using tissue obtained from miscarriages and stillbirths, this material can be difficult to obtain and may not always be suitable for research, partly because a genetic abnormality may have caused the loss of the fetus.
NIH also said it will soon examine another ethically fraught research area: work using human embryonic stem cells, which in 2024 were used in more than 600 NIH projects totaling $322 million. But the agency appears to be moving more slowly than it has with fetal tissue. It plans to seek public comment on “technologies that could reduce or replace” the cells.
from — Jacobs, P. (2026, January 23). Trump imposes new NIH funding ban on human fetal tissue research. Science. Retrieved March 26, 2026
~ ~ ~
HHS Bars Research Using Human Fetal Tissue from Elective Abortions
WASHINGTON — January 23, 2026 — The U.S. Department of Health and Human Services (HHS) today ended the permitted use of human fetal tissue from elective abortion in agency-funded research. The new policy advances the Trump Administration’s priorities to uphold the sanctity of human life and modernize biomedical science. HHS Secretary Robert F. Kennedy, Jr.’s directive applies consistent restrictions to grants, contracts, and programs administered across HHS.
“HHS is ending the use of human fetal tissue from elective abortions in agency-funded research and replacing it with gold-standard science,” Secretary Kennedy said. “The science supports this shift, the ethics demand it, and we will apply this standard consistently across the Department.”
The National Institutes of Health (NIH), which distributes most HHS medical research funding, is applying this policy across the NIH Intramural Research Program and all NIH-supported extramural research, including grants, cooperative agreements, other transaction awards, and research and development contracts. This action supersedes prior NIH guidance and reflects a shift toward validated research models better suited to today’s rapidly evolving scientific landscape, which includes advances in organoids, tissue chips, computational biology, and other cutting-edge platforms.
“NIH is pushing American biomedical science into the 21st century,” said NIH Director Jay Bhattacharya. “This decision is about advancing science by investing in breakthrough technologies more capable of modeling human health and disease. Under President Trump’s leadership, taxpayer-funded research must reflect the best science of today and the values of the American people.”
Secretary Kennedy’s announcement on the day of the National March for Life follows the HHS Office for Civil Rights’ actions this week to safeguard federal health care provider conscience rights and protect the dignity of human life. On December 9, 2025, the Centers for Medicare & Medicaid Services requested that the Maryland Insurance Administration cancel implementation of the Maryland Public Health Abortion Grant Program to ensure full compliance [PDF, 266 KB] with federal law.
Additionally, the Administration for Children and Families Office of Refugee Resettlement plans to revise the Biden-era Unaccompanied Children Program Foundational Rule to bring the program into compliance with the Hyde Amendment regarding funding or facilitation of abortion for unaccompanied alien minors in federal care.
from — HHS Bars Research Using Human Fetal Tissue from Elective Abortions. (2026, January 23). The Department of Health and HUman Services. Retrieved March 27, 2026
~ ~ ~
Fetal Tissue Research: A Weapon and a Casualty in the War Against Abortion
Highlights
Medical research using human fetal tissue obtained from abortions has benefited millions of people worldwide and holds great promise for the continued advancement of basic science, as well as for the development of lifesaving vaccines and therapies.
Since 1973, when abortion became legal nationwide, fetal tissue research has, time and again, become entangled in the abortion controversy.
The current controversy—set off by a series of heavily edited and misleading videos—grew out of abortion opponents’ long-standing campaign to vilify abortion and abortion providers, and it now threatens fetal tissue research itself.
The debate over using human fetal tissue in medical research came roaring back on the national policy agenda last summer when a group of antiabortion activists began releasing deceptively edited videos about Planned Parenthood’s handling of fetal tissue donations for this purpose. Fetal tissue research dates back to the 1930s, and has led to major advances in human health, including the virtual elimination of such childhood scourges as polio, measles and rubella in the United States.1,2 Today, fetal tissue is being used in the development of vaccines against Ebola and HIV, the study of human development, and efforts to treat and cure conditions and diseases that afflict millions of Americans.
To ensure it meets the highest ethical standards, fetal tissue research has been subject to stringent laws and regulations for decades. Abortion foes are now accusing health care providers and researchers of violating these laws and ethical standards, in hopes of undermining the right to abortion and ending fetal tissue research. These attacks not only threaten sexual and reproductive health and rights, but also pose a threat to the large numbers of people who could benefit from fetal tissue research, given the wide range of conditions that such research might ameliorate. Any impediment to ongoing scientific inquiry in the field caused by the current controversy would have substantial consequences.
Importance of Fetal Tissue Research
Unlike embryonic stem cell research, which uses cells from days-old embryos created through in vitro fertilization, fetal tissue research uses tissue derived from induced abortion of pregnancies at or after the ninth week.1,3 (Fetal tissue obtained from a miscarriage is often not suitable for research purposes because of concerns about potential chromosomal abnormalities that led to the miscarriage.3) Researchers most often acquire fetal tissue from a tissue bank or, sometimes, directly from a hospital or abortion clinic.4
Because it is not as developed as adult tissue and is able to adapt to new environments, fetal tissue is critical to the study of a wide variety of diseases and medical conditions, according to the American Society for Cell Biology.1 Researchers use fetal tissue—and cell cultures derived from such tissue, which can be maintained in a laboratory environment for decades—to study fundamental biological processes and fetal development. According to the U.S. Department of Health and Human Services, fetal tissue continues to be an important resource for researchers studying degenerative eye disease, human development disorders such as Down syndrome, and early brain development (relevant to understanding the causes of autism and schizophrenia).2
Fetal tissue has also been used to develop vaccines that have saved and improved the lives of billions of people worldwide.1,2,5 The 1954 Nobel Prize in Medicine was awarded for work using cell cultures originating from fetal tissue that led to the development of the polio vaccine. Vaccines for diseases such as measles, mumps, rubella, chickenpox, whooping cough, tetanus, hepatitis A and rabies were also created using fetal cell cultures, and researchers are now using fetal cells to develop vaccines against other diseases, including Ebola, HIV and dengue fever.
In addition, researchers use fetal tissue in transplantation research. Fetal tissue has several unique properties that make it particularly suitable for transplantation. Not only do fetal cells grow at a much faster rate than adult cells, they also elicit less of an immune response, which lowers the risk of tissue rejection.6 Clinical trials transplanting fetal cells are currently underway for people with spinal cord injury, stroke and ALS (Lou Gehrig’s disease), and may soon begin for those with Alzheimer’s disease, Parkinson’s disease and multiple sclerosis.1
The National Institutes of Health (NIH) has been supporting research using fetal tissue since the 1950s, and in FY 2014, NIH provided roughly $76 million for this work.3 According to an analysis of NIH research grants published in Nature, NIH funded 164 projects using fetal tissue in 2014, most often for research on infectious diseases, eye function and disease, and developmental biology (see chart).7,8
Many of the nation’s leading academic medical centers are involved in fetal tissue research.7,9,10 Researchers at the University of North Carolina at Chapel Hill are using cell cultures derived from fetal tissue for their work on hepatitis B and C—specifically, on how the viruses evade the human immune system and cause chronic liver diseases. At the University of Wisconsin-Madison, fetal cell cultures are used to study heart disease, including sudden cardiac arrest. At Stanford University, fetal tissue has been used to study Huntington’s disease, juvenile diabetes, autism and schizophrenia. And scientists at Colorado State University are conducting HIV research using fetal tissue.
.png)
Federal Law and Regulation
Soon after the U.S. Supreme Court’s Roe v. Wade decision in 1973 legalizing abortion nationwide, antiabortion leaders in Congress seized on fetal tissue research as a weapon in the war against abortion. Fetal tissue research was perhaps an inevitable target: It provided an aura of legitimacy to abortion itself and, at the same time, could be easily exploited to show how abortion “dehumanizes” the fetus.11 Accordingly, antiabortion activists employed graphic visuals to shock members of Congress, try to personify the fetus, and demonize abortion providers and the procedure itself.
This first incarnation of the controversy coincided with public revelations about the infamous Tuskegee syphilis study—a study that enrolled black men living in Alabama to investigate the long-term effects of syphilis. In 1973, an ad hoc advisory panel convened by the Department of Health, Education and Welfare (now the Department of Health and Human Services) concluded that, in retrospect, the study was “scientifically unsound” and “ethically unjustified.”12 In response to the Tuskegee revelations, Congress felt pressure to create protections for human research subjects, and by 1974, Congress passed the National Research Act. The law created the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research to develop guidelines on the ethical principles that apply to research on all human subjects, as well as on particular principles that apply to research involving fetuses and using fetal tissue.
The commission’s report on research on the fetus, issued in 1975, led to the creation of regulations during the Ford administration that set out the rules of the road for federally funded fetal tissue research. The regulations—which are still in effect—specify that “no inducements, monetary or otherwise, will be offered to terminate a pregnancy.” They also provide that “individuals engaged in the research will have no part in any decisions as to the timing, method, or procedures used to terminate a pregnancy.”
Fetal tissue research receded as a political issue until the late 1980s, when a group of NIH scientists sought approval from the Reagan administration for a proposed project involving the transplantation of fetal tissue. After deliberating on the request, the administration appointed an advisory panel—which included a chair and several members who were well-known opponents of abortion rights—to examine the ethical, legal and scientific questions raised by this type of research. In 1988, the panel issued its report and, despite its mixed composition, it concluded that “in light of the fact that abortion is legal and that the research in question is intended to achieve significant medical goals…the use of such tissue [for research] is acceptable public policy.”13
Key recommendations of the panel were later codified into law with the passage of the NIH Revitalization Act of 1993. The legislation won broad bipartisan support in Congress, including from several prominent senators with solid antiabortion records. Among them were Sens. Robert Dole (R-KS), a longtime advocate for people with disabilities, and Strom Thurmond (R-SC), who had a daughter with juvenile diabetes.14,15
The NIH Revitalization Act of 1993 added several provisions to the existing regulations governing fetal tissue research. One such provision prohibits anyone from accepting payment for human fetal tissue other than “reasonable payments associated with the transportation, implantation, processing, preservation, quality control, or storage of human fetal tissue.” Thus, although individuals may be compensated for any costs they incur in the acquisition, receipt or transfer of fetal tissue, they are prohibited from making a profit from these activities, regardless of whether the project is federally funded or not.
The law also imposes additional requirements when the donated tissue is used in federally funded research involving the transplantation of fetal tissue for therapeutic purposes. Among these are provisions for informed consent and prohibiting physicians and researchers from altering the timing or method used to terminate the pregnancy solely for the purposes of obtaining the tissue. Although all of these requirements technically apply only to federally funded transplantation research, as a practical matter, they set the standard for all research using fetal tissue. For example, the policies and procedures for fetal tissue donation issued by Planned Parenthood Federation of America and by the National Abortion Federation incorporate the substance of these federal requirements.16,17
State Policies
At the state level, fetal tissue donation is regulated by the Uniform Anatomical Gift Act (UAGA), versions of which are in effect in every state.13,18 According to an analysis by the Guttmacher Institute, 38 states and the District of Columbia have UAGA laws that explicitly treat fetal tissue the same way as other human tissue, permitting it to be donated by the woman for research, therapy or education. The remaining 12 states have laws that are silent, neither allowing nor disallowing the donation of fetal tissue (see map). UAGA also prohibits profiting from the sale or purchase of anatomical gifts for transplantation or therapy.
Fetal tissue donation and research are also regulated in some states by specific statutes. Often, these statutes incorporate many of the same standards set by federal law and regulations. For example, 12 states prohibit making a profit from the donation or transfer of fetal tissue for research purposes, and eight states require the woman’s consent for research.
Five states have laws that ban research using fetal tissue obtained from abortions throughout pregnancy. (Four other states also ban research using postabortion fetal tissue, but these laws have been struck down by the courts.) One of these states with a ban in effect, Indiana, also has a law that requires the disposal of postabortion fetal tissue in an established cemetery or by cremation, presumably precluding any possibility of donation for research.
.png)
Political Firestorm
The current furor over the use of fetal tissue in research ignited last summer, after the release of heavily edited videos purporting to capture undercover sting operations targeted at Planned Parenthood. The series of videos—released in close cooperation with members of Congress who want to ban abortion19—show an antiabortion activist posing as a representative of what turned out to be a sham biomedical research company, in frank discussions with various Planned Parenthood officials about tissue donation policies and reimbursement.
The fallout from the videos has been swift, severe and wide-ranging. The stated targets are Planned Parenthood, abortion providers and the legitimacy of abortion. The videos also threaten to undermine fetal tissue research itself, however, by sowing confusion, and by using graphic descriptions and images to turn the public against this research.
The primary goal of this current campaign has been to portray Planned Parenthood as callous and its providers as possibly criminal. Antiabortion policymakers have accused Planned Parenthood of violating several provisions of the NIH Revitalization Act of 1993, such as profiting from the sale of fetal tissue and altering the abortion procedure solely for the purpose of obtaining tissue. Opponents of abortion have also accused providers of using a procedure that violates the so-called “partial birth” abortion ban. As an instigator of the videos, David Daleiden explained in an interview with Politico, “For me, the goal was to document and illustrate for the public really, really clearly how Planned Parenthood harvests and sells the body parts of the babies that they abort.”20
Antiabortion elected officials ran with this narrative and immediately called for investigations of the organization. In October 2015, congressional leaders formed a special committee to carry out an official inquiry into Planned Parenthood—bringing the total number of investigations into Planned Parenthood in the House and Senate to five since the first video was released. In January 2016, the House’s first substantive piece of business was yet another attempt to cut off funding for Planned Parenthood, one of several such efforts recently to scale back abortion rights and women’s health care. Also, officials in 11 states have concluded investigations into claims that Planned Parenthood profited from fetal tissue donation, and each one of these investigations has cleared the organization of wrongdoing.21
Nonetheless, the grandstanding has continued unabated. Antiabortion leaders, lawmakers and all the Republican presidential candidates have used the opportunity to demonize abortion and paint a ghoulish picture of organ harvesting, all in an effort to gin up public disgust and attract public support for themselves and against abortion and Planned Parenthood. Indeed, the videos and the hype around them appear to have provoked at least four arson attacks on Planned Parenthood clinics since July 2015 and set the stage for yet another extreme act of violence in Colorado Springs over Thanksgiving weekend.10 It was there that Robert Lewis Dear Jr. allegedly killed three people and injured nine others at a Planned Parenthood health center. During his arrest, Dear shouted “no more baby parts,” suggesting that the constant barrage of inflammatory rhetoric around the fetal tissue issue over the prior months played a role in triggering his actions.22
High Stakes
Beyond the attacks on Planned Parenthood, however, the use of fetal tissue in research also is under direct attack. Since July, bills have been introduced in Congress and in several states that would make it more difficult to donate tissue or use fetal tissue in research. Other bills would ban fetal tissue research outright. This trend is almost certain to continue through 2016 as the issue is sure to be exploited in state and federal elections.
Meanwhile, the videos appear to have had a chilling effect on science. According to Theresa Naluai-Cecchini, a scientist at the Birth Defects Research Laboratory at the University of Washington (a federally funded entity that has served as a source of donated fetal tissue to researchers nationwide for more than 50 years), tissue donations have dropped dramatically since July 2015.10 Naluai-Cecchini told Mother Jones that if this trend continues, research that may save lives would take considerably longer.
Some scientists involved in fetal tissue research have been afraid to speak out.7 They have seen how abortion providers have been targeted, and now they too fear for their personal safety. Others have spoken out strongly to defend the importance of their work, pointing out that tissue that would otherwise be discarded has played a vital role in lifesaving medical advances and holds great promise for new breakthroughs. In an October 2015 open letter to Congress, 41 scientists called for the end to political interference with science and research: “Fetal tissue research has already saved and improved the lives of countless people. [We] cannot allow political agendas to undermine our nation’s legacy of leadership in medical and scientific innovation.”23 In another action, the Association of American Medical Colleges released a statement on January 6, 2016 signed by 59 academic medical centers, scientific societies and allied groups—from the University of Alabama School of Medicine to Duke University School of Medicine, from the University of Wisconsin-Madison to Tulane University School of Medicine.24 The statement expresses “grave concerns” about the numerous legislative proposals now in play in Congress and in many states, and it calls on lawmakers to reject any proposals that restrict access to fetal tissue for research.
Ironically, in the wake of all the heightened focus on fetal tissue donation, Planned Parenthood officials report they have seen an uptick in the number of women obtaining abortion who request that the fetal tissue be donated to research. The role that Planned Parenthood plays in providing postabortion tissue to researchers, however, is small: Just 1% of the approximately 700 health centers that are part of the Planned Parenthood network are equipped for fetal tissue donation. And in another response to the disinformation campaign and to try to quell some of the controversy, Planned Parenthood announced in October 2015 that its clinics will no longer seek reimbursement for their costs related to fetal tissue donation, even though the practice is perfectly legal and commonplace.
Bioethicist R. Alta Charo has argued that enabling the use of fetal tissue to advance scientific research for the benefit of humankind must be seen as something of a moral imperative. “Virtually every person in this country has benefited from research using fetal tissue,” she wrote in the New England Journal of Medicine. “Every child who’s been spared the risks and misery of chickenpox, rubella, or polio can thank the Nobel Prize recipients and other scientists who used such tissue in research yielding the vaccines that protect us….Any discussion of the ethics of fetal tissue research must begin with its unimpeachable claim to have saved the lives and health of millions of people.”25
As the full impact of the current firestorm surrounding fetal tissue research is still unfolding, it remains to be seen how much this research will continue be used as a weapon against abortion or become a serious target itself—or both. To be sure, the current controversy threatens not just access to safe and legal abortion and the providers who care for the women who seek this essential health service. It also threatens the millions of people globally who could benefit from fetal tissue research—and that includes nearly all of us, whatever our views on abortion rights may be.
from — Boonstra, H. D. & Guttmacher Institute. (2024, August 6). Fetal tissue research: a weapon and a casualty in the war against abortion. Guttmacher Institute. Retrieved March 27, 2026
March 27, 2026
Hudson Valley, New York
This is one of the words/ phrases you can’t say in the new Trump Regime. See a comprehensive list at the Forbidden Words Project.
image: butter © Holly Troy 2026
There’s nothing “free” about banning words or ideas.
from — Connelly, E. A. (2025, December 22). Federal Government’s Growing Banned Words List Is Chilling Act of Censorship. PEN America.
~ ~ ~
Climate Science Legal Defense Fund
see Silencing Science Tracker — silencingscience.org
Discover more from holly troy ~ sacred folly
Subscribe to get the latest posts sent to your email.
Ethical standards / of fetal tissue research / must be understood
LikeLike